Popular terms

Autoimmune topics
Autoimmune
Immune Disease
Autoimmune Disease
Immune Diseases
Autoimmune Diseases
Transplant
Immune Disorder
Autoimmune Disorder
Autoimmune Disorders
Infectious
Infectious Disease
Inflammatory Disease
Type 1 Diabetes
Proliferative Disorder
Recurrence

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Autoimmune patents



      

This page is updated frequently with new Autoimmune-related patent applications.




Date/App# patent app List of recent Autoimmune-related patents
06/16/16
20160169906 
 Methods for identifying autoimmune arthritis and for screening for inhibitor of activation of autoimmune arthritogenic t cells patent thumbnailMethods for identifying autoimmune arthritis and for screening for inhibitor of activation of autoimmune arthritogenic t cells
Provided are a method for identifying the presence or likelihood of autoimmune arthritis, the method comprising detecting (1) an anti-ribosomal protein l23a antibody or (2) ribosomal protein l23a-reactive cd4+ t cells in a sample derived from a subject; and a method for screening for a substance that inhibits the activation of autoimmune arthritogenic t cells, the method comprising the steps of bringing a test substance into contact with ribosomal protein l23a-reactive t cells, bringing the t cells into contact with ribosomal protein l23a or a fragment thereof, measuring the level of a proinflammatory cytokine secreted from the t cells, and analyzing the test substance-dependent change in the secretion level of the proinflammatory cytokine.. .
Kyoto University


06/16/16
20160168254 
 Rna-coded antibody patent thumbnailRna-coded antibody
The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.
Curevac Ag


06/16/16
20160168248 
 Regulatory t cell mediator proteins and uses thereof patent thumbnailRegulatory t cell mediator proteins and uses thereof
In particular methods of using these proteins and compounds, preferably antibodies, which bind or modulate (agonize or antagonize) the activity of these proteins, as immune modulators and for the treatment of cancer, autoimmune disease, allergy, infection and inflammatory conditions, e.g. Multiple sclerosis is disclosed.

06/16/16
20160168149 
 Purinone compounds as kinase inhibitors patent thumbnailPurinone compounds as kinase inhibitors
Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics Llc


06/16/16
20160168083 
 Therapeutic compounds patent thumbnailTherapeutic compounds
Or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula i, processes for preparing compounds of formula i, intermediates useful for preparing compounds of formula i and therapeutic methods for treating cancer or treating autoimmune diseases or preventing transplant rejection using compounds of formula i..

06/16/16
20160166708 
 Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer patent thumbnailPro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (p2pdox) with antibodies or antigen-binding fragments thereof (adcs), with targetable construct peptides or with other targeting molecules that are capable of delivering the p2pdox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the adc or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-pdox) is released intracellularly.
Immunomedics, Inc.


06/16/16
20160166692 
 Rna-coded antibody patent thumbnailRna-coded antibody
The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.
Curevac Ag


06/16/16
20160166691 
 Rna-coded antibody patent thumbnailRna-coded antibody
The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.
Curevac Ag


06/16/16
20160166690 
 Rna-coded antibody patent thumbnailRna-coded antibody
The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.
Curevac Ag


06/16/16
20160166664 
 Compositions and methods for induction of antigen-specific tolerance patent thumbnailCompositions and methods for induction of antigen-specific tolerance
The present invention utilizes carrier particles to present antigen peptides and proteins to the immune system in such a way as to induce antigen specific tolerance. The carrier particle is designed in order to trigger an immune tolerance effect.
Northwestern University


06/16/16
20160166636 

Modified peptides and their use for treating chronic inflammatory diseases


The present invention relates to a peptide, or a salt thereof, comprising or consisting of the amino acid sequence ihmvyskrsgkprgyafiey, comprising one or more post-translational modifications, for the treatment, prevention or amelioration of a hyper autophagy-related autoimmune disease or disorder.. .
Centre National De La Recherche Scientifique


06/16/16
20160166611 

Method of preparing injection solution


A method of preparing an injection solution includes: (1) storing a mixture of a blood sample and a divalent cation chelating agent at a temperature between 2 and 12 degrees celsius for a period of from 3 hours to 72 hours so as to have the mixture with two or more separate layers, wherein a liquid in one of the separate layers contains small somatic stem cells such as sb cells; (2) collecting the liquid from the mixture; and (3) after collecting the liquid from the mixture, mixing the liquid with a solution free from ca2+ into the injection solution. The injection solution can be used for an autoimmune disease, such as ankylosing spondylitis, rheumatoid arthritis, or grover's disease..
Stembios Technologies, Inc.


06/09/16
20160161498 

Diagnostic pediatric acute-onset neuropsychiatric syndrome (pans) and pediatric autoimmune neuropsychiatric disorder associated with streptococci infection (pandas)


The present invention provides a panel of at least five clinical analyses or tests (using serum samples) to determine the risk of pediatric acute-onset neuropsychiatric syndrome (pans) and/or pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (pandas) in an individual. These include enzyme linked immunosorbent assays (elisas) to measure antibody titers against neuronal antigens present in the brain; the neuronal antigens include lysoganglioside, tubulin, dopamine receptor d1, dopamine receptor d2, serotonin receptor 5ht2a, and serotonin receptor 5ht2c.

06/09/16
20160161497 

Diagnostic pediatric acute-onset neuropsychiatric syndrome (pans) and pediatric autoimmune neuropsychiatric disorder associated with streptococci infection (pandas)


The present invention provides a panel of at least five clinical analyses or tests (using serum samples) to determine the risk of pediatric acute-onset neuropsychiatric syndrome (pans) and/or pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (pandas) in an individual. These include enzyme linked immunosorbent assays (elisas) to measure antibody titers against neuronal antigens present in the brain; the neuronal antigens include lysoganglioside, tubulin, dopamine receptor d1, dopamine receptor d2, serotonin receptor 5ht2a, and serotonin receptor 5ht2c.

06/09/16
20160160220 

Methods and compositions for treating autoimmune disorders by targeting kv1.3 ion channels with functionalized lipid-derived nanovesicles


Synthesis and pharmaceutical compositions of antibody-functionalized nanovesicles encapsulating ion channel knockout sirna, and methods of treating autoimmune diseases associated with increased expression and/or hyperactivity of t cells by selectively targeting memory t cells with the nanoparticles, which deliver their sirna cargo into the cytosol of the tm cell thus reducing ion channel expression and decreasing ca2+ influx.. .
North Carolina Agricultural And Technical State University


06/09/16
20160160218 

Use of aptamers in therapy and/or diagnosis of autoimmune diseases


The present invention is directed to an aptamer comprising or consisting of the nucleic acid sequence of seq id no. 1, seq id no.
Max-delbrueck-centrum Fuer Molekulare Medizin


06/09/16
20160159802 

18f-labelled folates


The present invention is directed towards new 18f-folate radiopharmaceuticals, wherein the fluorine-18 is covalently linked to the aminobenzoyl moiety, which connects the condensed pyrimidine heterocycle to the amino acid portion within folate structures, as well as their precursors and their non-radioactive references, a method of their preparation, as well as their use in diagnosis of a cell or population of cells expressing a folate-receptor and monitoring of cancer and inflammatory and autoimmune diseases and therapy thereof.. .
Merck & Cie


06/09/16
20160159800 

Mk2 inhibitors


Or a pharmaceutically acceptable salt thereof. The compounds can be used in the treatment of immune, autoimmune, inflammatory diseases, cardiovascular diseases, infectious diseases, bone resorption disorders, neurodegenerative diseases or proliferative diseases..

06/09/16
20160159775 

Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor


Benzoimidazol-2-yl pyrimidines, purification methods for the same, and pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritus.. .
Janssen Pharmaceutica Nv


06/09/16
20160158366 

Clathrin therapeutic for autoimmune diseases


The invention in suitable embodiments is directed to purified clathrin protein therapeutics. In one aspect, one or more purified clathrin protein therapeutic, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more clathrin heavy chain protein and isoforms thereof, forms one or more type of therapeutic agent for treating an autoimmune disease, condition, or disorder in vivo or in vitro..

06/09/16
20160158352 

Apoptotic cell-mediated induction of antigen specific regulatory t-cells for the therapy of autoimmune diseases in animals and humans


The invention provides methods of tolerizing or treating a subject suffering from an autoimmune or autoinflammatory disease or disorder to an antigen associated with the autoimmune disease or disorder. The invention also features kits for carrying out the methods of the invention..
The United States Of America, As Represented By The Secretary, Department Of Health & Human Servic


06/09/16
20160158318 

Methods for treating scleroderma by administering a soluble ctla4 molecule


The present invention relates to compositions and methods for treating autoimmune diseases by administering to a subject a ctla4 molecule that block endogenous b7 molecules from binding their ligands.. .
Bristol-myers Squibb Company


06/09/16
20160158218 

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases


Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-xl proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-xl protein.. .
Abbvie Inc.


06/02/16
20160153984 

Methods of detecting autoimmune or immune-related diseases or conditions


This invention provides methods of using phagocytic cells alone or in combination with non-phagocytic cells in the diagnosis, prognosis, or monitoring of autoimmune or immune-related diseases or conditions. The invention also provides methods of using phagocytic cells alone or in combination with non-phagocytic cells to identify markers of autoimmune or immune-related diseases or conditions..
President And Fellows Of Harvard College


06/02/16
20160152951 

Regulatory b cells (tbregs) and their use


Regulatory b cells (tbreg) are disclosed herein. These regulatory b cells express cd25 (cd25+) a pan b cell marker such as b220 (b220+), and also express cd19 (cd19+).
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


06/02/16
20160152721 

Silent fc variants of anti-cd40 antibodies


The present invention relates to silent fc variants of anti-cd40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.. .
Novartis Ag


06/02/16
20160152706 

Rna-coded antibody


The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.
Curevac Ag


06/02/16
20160152704 

Cadherin 15 agonists


Cdh15 has been identified as a receptor for a peptide which has an inhibitory effect of the migration of t cells. Agonists of this receptor have applications in the treatment and/or prophylaxis of conditions associated with the migration of t-cells, including t cell auto-reactivity, t cell mediated chronic inflammatory disease and autoimmune disease.
The University Of Birmingham


06/02/16
20160152699 

Pan-elr+ cxc chemokine antibodies


Antibodies are provided that specifically bind seven human elr+ cxc chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (ibd), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer..
Eli Lilly And Company


06/02/16
20160152691 

Rna-coded antibody


The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.
Curevac Ag


06/02/16
20160152628 

Tricyclic pyrido-carboxamide derivatives as rock inhibitors


The present invention provides compounds of formula (i): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective rock inhibitors.
Bristol-myers Squibb Company


06/02/16
20160152627 

Tricyclic pyrido-carboxamide derivatives as rock inhibitors


The present invention provides compounds of formula (i): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective rock inhibitors.
Bristol-myers Squibb Company


06/02/16
20160151471 

Inducible regulatory t-cell generation for hematopoietic transplants


The present invention provides methods and compositions for converting non-tregs into tregs. The converted tregs are referred to as inducible tregs (itregs).
The Trustees Of The University Of Pennsylvania


06/02/16
20160151454 

Leukolectins and uses thereof


The present invention relates to a polypeptide, described as a lectin, its encoding nucleic acid sequence and antibodies to the polypeptide and their use in various medical applications, particularly for treating or preventing an autoimmune disorder, an inflammatory disorder or damaged skin in an animal.. .
Leukolect As


05/26/16
20160146831 

Antibody and cytokine biomarker profiling for determination of patient responsiveness


Compositions and methods are provided for prognostic classification of autoimmune disease patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest. The patterns of circulating blood levels of serum autoantibodies and/or cytokines provides for a signature pattern that can identify patients likely to benefit from therapeutic intervention as well as discriminate patients that have a high probability of responsiveness to a therapy from those that have a low probability of responsiveness.
The Board Of Trustees Of The Leland Stanford Junior University


05/26/16
20160146807 

Cxcr4 and robo1 expression as markers for autoimmune diabetes


Cxcr4 and robo-1 are biomarkers associated with type 1 diabetes. Expression of cxcr4 and robo-1 in peripheral cd3 t cells is substantially higher in patients with autoimmune diabetes (type 1 diabetes) than in non-diabetic patients.
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College


05/26/16
20160145346 

Rna-coded antibody


The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.
Curevac Ag


05/26/16
20160145336 

Effector-deficient anti-cd32a antibodies


Effector-deficient anti-cd32a monoclonal antibodies are encompassed, as are method and uses for treating cd32a-mediated diseases and disorders, including, thrombocytopenia, allergy, hemostatic disorders, immune, inflammatory, and autoimmune disorders.. .
Adventist Health System/sunbelt Inc.


05/26/16
20160145335 

Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease


The present invention provides chimeric and humanized versions of anti-cd19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human cd19 antigen and that may mediate adcc, cdc, and/or apoptosis for the treatment of b cell diseases and disorders, such as, but not limited to, b cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (gvhd), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients..
Medimmune, Llc


05/26/16
20160145294 

Antagonists of cb1 receptor


The invention relates to an antagonist of cb1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.. .
Universite De Bordeaux


05/26/16
20160145249 

Alxr agonist compound


The present invention provides a compound having alxr agonist activity. Specifically, the invention provides a compound having alxr agonist activity represented by general formula (i) wherein all the symbols are as defined in the specification, a salt thereof, a solvate thereof, or a prodrug thereof as well as an agent containing the same as an active ingredient for preventing and/or treating an alxr-associated disease, such as an inflammatory bowel disease, an autoimmune disease, a chronic inflammatory disease, asthma, pulmonary fibrosis, atopic dermatitis, ischemia-reperfusion injury, myocardial infarction, or alzheimer's disease..
Ono Pharmaceutical Co., Ltd.


05/26/16
20160145206 

N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and n-(4- hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use


The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted n-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamide compounds (collectively referred to herein as hmc compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, inflammation and/or joint destruction and/or bone loss; disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; inflammatory and autoimmune disorders, for example, rheumatoid arthritis; psoriasis; psoriatic arthritis; chronic obstructive pulmonary disease (copd); asthma; atherosclerosis; inflammatory bowel disease; ankylosing spondylitis; multiple sclerosis; systemic lupus erythematosus; sjogren's syndrome; a disorder associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, or paget's disease; cancer, such as a haematological malignancy, such as multiple myeloma, leukemia, or lymphoma, or a solid tumour cancer, such as bladder cancer, breast cancer (female and/or male), colon cancer, renal cell carcinoma, kidney cancer, lung cancer, pancreatic cancer, gastric cancer, prostate cancer, brain cancer, skin cancer, thyroid cancer, basal cell ameloblastoma, or melanoma; a disorder associated with fibrosis, such as systemic sclerosis or scleroderma; or a rare vasculitide, such as behçet's disease.
Pimco 2664 Limited


05/26/16
20160144014 

Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease


Compositions consisting of bioactive molecules derived from the microbiota of a mammal are provided herein. When administered orally with a colonic delivery system, the compositions are useful for the prophylaxis and treatment of diseases, in particular inflammatory, autoimmune and infectious diseases.
Riken


05/26/16
20160143870 

Ido inhibitors


There are disclosed compounds of formula (i) that modulate or inhibit the enzymatic activity of indoleamine 2,3-di-oxygenase (ido), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.. .
Bristol-myers Squibb Company




Autoimmune topics: Autoimmune, Immune Disease, Autoimmune Disease, Immune Diseases, Autoimmune Diseases, Transplant, Immune Disorder, Autoimmune Disorder, Autoimmune Disorders, Infectious, Infectious Disease, Inflammatory Disease, Type 1 Diabetes, Proliferative Disorder, Recurrence

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Autoimmune for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.4704

5188

2 - 1 - 102